



Bulletin from Annual General Meeting in Boule Diagnostics AB on May 4, 2023

The Annual General Meeting 2023 (the "AGM") decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2022. The AGM resolved that the company's accumulated profits shall be carried forward and that no dividend shall be paid for the financial year 2022.

The AGM also decided to discharge the board members and the CEO from liability for 2022.

The AGM approved the nominating committee's revised proposal that the board shall consist of five board members.

The AGM decided that the remuneration to the chairman of the board shall amount to SEK 500,000 (same as for 2022) and that the remuneration to the other board members shall be SEK 250,000 (same as for 2022) each. In addition, it was approved that SEK 120,000 (same as for 2022) will be the total remuneration to the audit committee, to be distributed within itself, as well as an amount of up to SEK 50,000 that the board can use for special initiatives. The total remuneration to the board is hence SEK 1,670,000.

The AGM also decided that the remuneration to the auditor as previous will be on specified current account approved by the board.

The AGM decided that the board until the end of the next Annual General Meeting will consist of the members Karin Dahllöf, Thomas Eklund, Torben Jørgensen, Yvonne Mårtensson and Emil Hjalmarsson through re-election with Torben Jørgensen elected chairman of the board. Jon Risfelt has declined re-election.

Öhrlings PriceWaterhouseCoopers AB was re-elected as the company's auditor, with Lars Kylberg as auditor in charge, until the end of the Annual General Meeting of 2024.

The AGM approved the proposed principles and instructions for the nomination committee.

The AGM approved the board's presented remuneration report for 2022.

The AGM approved the board's proposal to be authorized to increase share capital through the issue of new shares, warrants and/or convertibles.

The AGM approved the board's proposal to be authorized to make decisions on the acquisition and/or transfer of own shares.

Complete proposals regarding the AGM's decisions are available in Swedish on Boule's website www.boule.com.

For more information, please contact:

Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Jan Benjaminson, CFO, Boule Diagnostics AB, phone +46 (0)70-666 93 88



About Boule Diagnostics AB (publ)

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 548 million in 2022 and has more than 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. <http://www.boule.com>

The information was submitted for publication, through the agency of the contact person set out above, at XX:XX CEST on May 4, 2023.